Pharmaceutical Companies Commit to Most Favored Nation Pricing Under Trump Administration
Nine major pharmaceutical companies, including Amgen and Merck, have agreed to Most Favored Nation pricing as part of an initiative from the Trump administration aimed at reducing prescription drug costs, affecting Medicare, Medicaid, and uninsured patients. This pricing model, set to take effect in January 2026, is projected to save approximately $12 billion annually and will lead to significant price reductions for drugs like Plavix and insulin. Additionally, the agreements include over $150 billion in U.S. manufacturing investments.
Theia Market Signal Identification - AI Assisted
U.S. Rep. Dan Meuser announced that nine major pharmaceutical companies, including Amgen and Merck, have agreed to Most Favored Nation (MFN) pricing, following President Trump's executive order aimed at reducing U.S. prescription drug costs.
This brings total participation to 14 of the 17 largest global drug manufacturers. The MFN pricing system, effective January 2026, is expected to provide approximately $12 billion in annual savings and will impact Medicare, Medicaid, and uninsured patients.
Significant price reductions for drugs like Plavix and insulin are also expected. Additionally, the agreements involve over $150 billion in U.S. manufacturing investments. Separately, the Pennsylvania House passed legislation ensuring vaccine access through pharmacists amidst federal policy changes, while U.S.
Sen. Dave McCormick supported key provisions in the National Defense Authorization Act for Fiscal Year 2026 to enhance military readiness and infrastructure in Pennsylvania.
Comments